David J Kerr

List of Publications by Year
in descending order

108 papers	12,834 citations	46918 47 h-index	33814 99 g-index
109 all docs	109 docs citations	109 times ranked	16141 citing authors

#	Article	IF	Citations
1	Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, The, 2007, 370, 2020-2029.	6.3	1,244
2	Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nature Genetics, 2013, 45, 136-144.	9.4	851
3	A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics, 2007, 39, 984-988.	9.4	754
4	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2005, 23, 8664-8670.	0.8	607
5	Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer, 2009, 9, 489-499.	12.8	602
6	Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 1261-1270.	0.8	593
7	A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics, 2008, 40, 623-630.	9.4	514
8	Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nature Genetics, 2008, 40, 1426-1435.	9.4	498
9	Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 17-24.	0.8	487
10	A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nature Genetics, 2007, 39, 1315-1317.	9.4	463
11	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet, The, 2020, 395, 350-360.	6.3	364
12	Validation Study of a Quantitative Multigene Reverse Transcriptaseâ€“Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer. Journal of Clinical Oncology, 2011, 29, 4611-4619.	0.8	341
13	Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 2010, 42, 973-977.	9.4	335
14	Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nature Genetics, 2008, 40, 26-28.	9.4	277
15	Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews Clinical Oncology, 2011, 8, 587-596.	12.5	259
16	Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet, The, 2003, 361, 368-373.	6.3	233
17	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	3.7	227
18	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. Journal of Clinical Oncology, 2007, 25, 4569-4574.	0.8	220

#	Article	IF	Citations
19	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 1031-1039.	0.8	216
20	Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 2012, 44, 770-776.	9.4	210
21	Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer. PLoS Genetics, 2011, 7, e1002105.	1.5	188
22	<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trials. Journal of Pathology, 2016, 238, 562-570.	2.1	185
23	Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. Journal of Clinical Oncology, 2013, 31, 4297-4305.	0.8	181
24	Designing deep learning studies in cancer diagnostics. Nature Reviews Cancer, 2021, 21, 199-211.	12.8	175
25	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 2019, 10, 2154.	5.8	172
26	Novel therapeutic strategies: targeting epithelialâ€“mesenchymal transition in colorectal cancer. Lancet Oncology, The, 2021, 22, e358-e368.	5.1	133
27	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2016, 17, 1543-1557.	5.1	129
28	Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. New England Journal of Medicine, 2007, 357, 360-369.	13.9	124
29	Open access chemical and clinical probes to support drug discovery. Nature Chemical Biology, 2009, 5, 436-440.	3.9	122
30	A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Scientific Reports, 2015, 5, 10442.	1.6	109
31	An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis, 2019, 8, 13.	2.1	99
32	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncology, The, 2022, 23, e251-e312.	5.1	94
33	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS. Gut, 2015, 64, 111-120.	6.1	93
34	Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature Clinical Practice Oncology, 2004, 1, 39-43.	4.3	85
35	Clinical development of gene therapy for colorectal cancer. Nature Reviews Cancer, 2003, 3, 615-622.	12.8	84
36	Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial. Journal of Clinical Oncology, 2010, 28, 4575-4580.	0.8	81

#	Article	IF	Citations
37	Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. European Journal of Cancer, 2017, 84, 228-238.	1.3	81
38	Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. Journal of Pathology, 2013, 229, 441-448.	2.1	80
39	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. International Journal of Cancer, 2017, 140, 2701-2708.	2.3	76
40	Multilevel genomics of colorectal cancers with microsatellite instabilityâ€"clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine, 2017, 9, 46.	3.6	71
41	Building capacity for sustainable research programmes for cancer in Africa. Nature Reviews Clinical Oncology, 2014, 11, 251-259.	12.5	68
42	Chromatin organisation and cancer prognosis: a pan-cancer study. Lancet Oncology, The, 2018, 19, 356-369.	5.1	67
43	Can We Treat Cancer for a Dollar a Day? Guidelines for Low-Income Countries. New England Journal of Medicine, 2010, 363, 801-803.	13.9	65
44	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology and Hepatology, 2018, 3, 635-643.	3.7	60
45	Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. British Journal of Cancer, 2016, 115, 266-272.	2.9	57
46	Prognostic markers for colorectal cancer: estimating ploidy and stroma. Annals of Oncology, 2018, 29, 616-623.	0.6	56
47	Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. Oncotarget, 2012, 3, 1348-1355.	0.8	54
48	Redesigning cancer care. BMJ: British Medical Journal, 2002, 324, 164-166.	2.4	52
49	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer, 2019, 121, 474-482.	2.9	41
50	Challenges and solutions in patient treatment strategies for stage II colon cancer. Gastroenterology Report, 2019, 7, 151-161.	0.6	41
51	Variation at 2q35 (PNKDandTMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. Human Molecular Genetics, 2016, 25, 2349-2359.	1.4	37
52	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. International Journal of Cancer, 2019, 144, 2161-2168.	2.3	34
53	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. Journal of Clinical Oncology, 2016, 34, 1182-1189.	0.8	32
54	The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management. Familial Cancer, 2022, 21, 197-209.	0.9	31

#	Article	IF	Citations
55	Defective Mismatch Repair in Colon Cancer: A Prognostic Or Predictive Biomarker?. Journal of Clinical Oncology, 2010, 28, 3210-3212.	0.8	29
56	'Toxgnostics': an unmet need in cancer medicine. Nature Reviews Cancer, 2014, 14, 440-445.	12.8	29
57	Clinical cancer research: the past, present and the future. Nature Reviews Clinical Oncology, 2014, 11, 663-669.	12.5	29
58	The Predictive and Prognostic Value of Sex inÂEarly-Stage Colon Cancer: A Pooled Analysis ofÂ33,345 Patients from the ACCENT Database. Clinical Colorectal Cancer, 2013, 12, 179-187.	1.0	27
59	Genomeâ€wide association study and metaâ€analysis in Northern European populations replicate multiple colorectal cancer risk loci. International Journal of Cancer, 2018, 142, 540-546.	2.3	26
60	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival. Clinical Cancer Research, 2015, 21, 3453-3461.	3.2	24
61	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). European Journal of Surgical Oncology, 2020, 46, 955-966.	0.5	22
62	British Lessons on Health Care Reform. New England Journal of Medicine, 2009, 361, e21.	13.9	16
63	How Useful Are International Treatment Guidelines in Low- and Middle-Income Countries?. Journal of Global Oncology, 2017, 3, 441-443.	0.5	16
64	Intratumoral stromal morphometry predicts disease recurrence but not response to 5â€fluorouracilâ€”results from the <scp>QUASAR</scp> trial of colorectal cancer. Histopathology, 2018, 72, 391-404.	1.6	16
65	Is sidedness prognostically important across all stages of colorectal cancer?. Lancet Oncology, The, 2016, 17, 1480-1482.	5.1	15
66	Confirmation that somatic mutations of betaâ€2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial. Histopathology, 2019, 75, 236-246.	1.6	15
67	A Trial of Adjuvant Therapy in Colorectal Cancer: The VICTOR Trial. Clinical Colorectal Cancer, 2003, 3, 58-60.	1.0	14
68	Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer. Oncoscience, 2015, 2, 508-516.	0.9	11
69	The Essentials of Multiomics. Oncologist, 2022, 27, 272-284.	1.9	11
70	Bevacizumabâ€”has it reached its final resting place?. Nature Reviews Clinical Oncology, 2011, 8, 195-196.	12.5	10
71	Addressing unwarranted variations in colorectal cancer outcomes: a conceptual approach. Nature Reviews Clinical Oncology, 2016, 13, 706-712.	12.5	10
72	The value of additional bevacizumab in patients with highâ€risk stromaâ€high colon cancer. A study within the QUASAR2 trial, an openâ€label randomized phase 3 trial. Journal of Surgical Oncology, 2018, 117, 1043-1048.	0.8	10

#	Article	IF	Citations
73	Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients. Journal of Human Genetics, 2011, 56, 58-63.	1.1	9
74	Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer. Journal of Human Genetics, 2012, 57, 709-716.	1.1	9
75	Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer. Journal of Physical Education and Sports Management, 2017, 3, a001362.	0.5	9
76	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. Oncologist, 2020, 25, e1-e4.	1.9	9
77	Celecoxib for Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2021, 325, 1257.	3.8	9
78	Personalising cancer medicine with prognostic markers. EBioMedicine, 2021, 72, 103577.	2.7	9
79	Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial. Anticancer Research, 2015, 35, 1641-5.	0.5	9
80	Stromal composition predicts recurrence of early rectal cancer after local excision. Histopathology, 2021, 79, 947-956.	1.6	8
81	Cancer and COVID-19 Experiences at African Cancer Centers: The Silver Lining. JCO Global Oncology, 2021, 7, 410-415.	0.8	7
82	Genomeâ€wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. International Journal of Cancer, 2021, 149, 1713-1722.	2.3	7
83	Stage II colon cancer. Chinese Clinical Oncology, 2013, 2, 16.	0.4	7
84	Strategies for Sustainable Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e11-e15.	1.8	6
85	Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia. Journal of Global Oncology, 2018, 4, 1-4.	0.5	6
86	Cetuximab plus chemotherapy in patients with advanced NSCLC. Nature Reviews Clinical Oncology, 2009, 6, 499-500.	12.5	5
87	Tailoring treatment and trials to prognosis. Nature Reviews Clinical Oncology, 2013, 10, 429-430.	12.5	5
88	EU data protection regulationâ€”harming cancer research. Nature Reviews Clinical Oncology, 2014, 11, 563-564.	12.5	5
89	QUASAR Results: The Prognostic Validity of a Colon Cancer Recurrence Score and the Role of Multigene Profiles in Determining Risk. Current Colorectal Cancer Reports, 2010, 6, 144-147.	1.0	4
90	Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. Current Colorectal Cancer Reports, 2014, 10, 363-371.	1.0	4

#	Article	IF	Citations
91	Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. EBioMedicine, 2021, 71, 103547.	2.7	4
92	Should We Adapt Existing Quality Systems for Use in Low- and Middle-Income Countries?. Journal of Oncology Practice, 2015, 11, 370-371.	2.5	3
93	Facing the Global Challenges of Access to Cancer Medication. Journal of Global Oncology, 2018, 4, 1-7.	0.5	3
94	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. Oncologist, 2020, 25, e1428-e1432.	1.9	3
95	Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced handâ€foot syndrome. International Journal of Cancer, 2022, , .	2.3	3
96	NTRAC pioneering a virtual model. Lancet Oncology, The, 2003, 4, 393.	5.1	2
97	Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment. Nature Clinical Practice Oncology, 2008, 5, 250-251.	4.3	1
98	Better value cancer care for the 21st century. Annals of Oncology, 2011, 22, 2541-2545.	0.6	1
99	Toxgnostics: predicting and preventing chemotherapy-induced side effects. Personalized Medicine, 2014, 11, 683-685.	0.8	1
100	Two errors. Lancet, The, 2004, 364, 907.	6.3	0
101	Today's Science, Tomorrow's Patient: the Pivotal Role of Tissue, Clinical Data and Informatics in Modern Drug Development. , 2006, , 185-209.		0
102	Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?. Nature Clinical Practice Oncology, 2006, 3, 480-481.	4.3	0
103	Biomarkers in Oncology. , 2015, , 185-188.		0
104	Biomarkers in oncology. , 2021, , 195-202.		0
105	Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction. , 0, , 691-710.		0
106	Donors, Noncommunicable Diseases, and Universal Health Coverage to High-quality Healthcare: An Opportunity for Action on Global Functions for Health. Journal of Epidemiology and Global Health, 2018, 8, 236.	1.1	0
107	Virtual Oncology in the Time of COVID-19 Pandemic: Moving Forward!. Innovations in Digital Health Diagnostics and Biomarkers, 2021, 1, 19-20.	0.5	0
108	Capecitabine/irinotecan combination regimens in colorectal cancer. Oncology, 2002, 16, 27-9.	0.4	0